New insider activity at Jazz Pharmaceuticals ( (JAZZ) ) has taken place on December 9, 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Patricia Carr, the Senior Vice President and Chief Accounting Officer of Jazz Pharmaceuticals, has recently sold 4,660 shares of the company’s stock. This transaction was valued at an impressive $797,777.
Recent Updates on JAZZ stock
Recent developments in Jazz Pharmaceuticals’ stock have seen several price target adjustments from analysts, driven primarily by positive outcomes from the Phase 3 HERIZON-GEA-01 study. UBS downgraded the stock to Neutral, citing a balanced risk/reward profile after a significant stock move and the recent oncology momentum being reflected in the valuation. In contrast, Truist, Baird, BofA, and Wells Fargo raised their price targets, highlighting the promising potential of Jazz’s drug Ziihera, which is seen as a ‘pipeline-in-a-drug’ with significant sales potential in HER2+ cancers. The favorable study results suggest Ziihera could become a new standard of care in gastric cancer, with substantial market opportunities both in the U.S. and globally.
Spark’s Take on JAZZ Stock
According to Spark, TipRanks’ AI Analyst, JAZZ is a Neutral.
Jazz Pharmaceuticals’ overall score is driven by strong earnings call results and positive corporate events, indicating strategic growth potential. However, financial performance challenges and valuation concerns weigh on the score.
To see Spark’s full report on JAZZ stock, click here.
More about Jazz Pharmaceuticals
YTD Price Performance: 36.51%
Average Trading Volume: 985,120
Technical Sentiment Signal: Buy
Current Market Cap: $10.31B